A type 2 diabetes drug has also allowed obese patients to lose weight after more than a year of treatment. This is the result of a clinical trial at Yale University.
According to the World Health Organization (), 13% of the world’s population suffers from (a more than 30 million, or more than 600 million people. If the figure on the scales does not necessarily reflect the health of the person on board, obesity is known to chronic as the type 2, the and other health problems that can decrease the.
A drug already licensed to treat type 2 diabetes, tirzepatide, has allowed participants one led by doctors at Yale University of . The drug was tested according to three different – 5, 10 and 15 mg – and injected under the skin once a week for 72 weeks. The 2,500 patients are all obese, with an average weight of 104 pounds, and also have at least one complication related to their weight. Diabetic patients are excluded from the clinical trial, but those with pre-diabetes have been included.
An effective anti-diabetic for weight loss
Participants treated with 5 mg tirzepatide lost an average of 15% At the end of 72 weeks, those who took 10 and 15 mg lost 19.5 and 20.9% of their body weight, respectively. This is only 3% for people who have received one . On average, tirzepatide reduced participants’ fat mass by 33.9%, improving the fat-to-weight-to-weight ratio and bringing it closer to that of sports-based weight loss strategies. and food or the . In addition to the decrease in body mass, tirzepatide has been used to restore the in normal values in pre-diabetic patients. This could reduce the risk of developing one kidney, liver and type 2 diabetes.
On the side effects, tirzepatide caused side effects gastrointestinal disorders such as nausea, vomiting and des of mild to moderate severity. Eleven people died during the of the clinical trial, both in the placebo group and in the treatment group. As the clinical trial ran from December 2019 to April 2022, several participants died from Covid-19, others a or a cardiac arrest. Deaths that do not appear to be directly related to tirzepatide. Further results are needed for tirzepatide to obtain a as part of the treatment of obesity.